Long-Term Debt: Molecular Partners AG (MOLN)

Brandmark of Molecular Partners Ltd (MOLN)

Molecular Partners AG (MOLN) is implementing robotic systems to accelerate the analysis of DARPin anti-tumor proteins, minimizing manual labor in laboratories. Molecular Partners AG (MOLN) generates revenue by granting pharmaceutical giants access to its platform, receiving royalties and milestone payments. Long-term debt stands at 0.00. The price trend for this company on the GURU.Markets platform is shown below.

MOLN (Molecular Partners) Company Long-Term Debt history from 07/04/2022 to 10/29/2026

Molecular Partners - analytical breakdowns and key metrics (MOLN)

- current quotes and average value forecast:
Stock Quotes molecularpartners.com|MOLN - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Molecular Partners|MOLN - Total Company Value
- book capitalization data:
Net Assets per Single Share Molecular Partners|MOLN - Company Book Value|Market-to-Book Ratio molecularpartners.com|MOLN - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Molecular Partners AG|MOLN - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Molecular Partners Ltd|MOLN - Company Total Debt|Debt to Net Assets Ratio Molecular Partners|MOLN - Company Long-Term Debt|Current Liabilities Molecular Partners|Quick Liquidity molecularpartners.com
- net income and valuation multiples indicators:
MOLN - Net Profit
Fundamental company valuation:molecularpartners.com
Core merchandise of Molecular Partners

Protein design robotization at Molecular Partners AG (MOLN) requires significant infrastructure capital expenditures and multi-year clinical trials. This indicator aggregates all obligations with maturities exceeding one year, reflecting the issuer's long-term credit burden. Analyzing this metric allows for an assessment of the company's financial stability and default risk during portfolio rebalancing. By evaluating the trend of the business's long-term debt capital, an investor can filter out market noise and determine the real value of the debt.

Competitors of Molecular Partners AG (MOLN)

GERN - Company Long-Term Liabilities|NBTX - Company Long-Term Debt|Long-Term Debt Bicycle Therapeutics PLC|CytomX Therapeutics Inc (CTMX) - Company Long-Term Debt|CATX (Perspective Therapeutics, Inc.) - Company Long-Term Debt|Company Long-Term Debt Genelux Corp.|Long-Term Debt Oncolytics ONCY|Company Long-Term Debts LSTA|moleculin.com (MBRX) - Long-Term Indebtedness|Galera Therapeutics, Inc. - Company Long-Term Liabilities|Molecular Templates Corporation (MTEM) - Long-Term Debt